{"prompt": "['NET-PRO Protocol v1.3', 'April 2022', 'Malignant carcinoid tumor of the small intestine, unspecified', 'ICD-10', 'GEP', 'C7A.019', 'portion', 'ICD-10', 'GEP', 'C7A.020', 'Malignant carcinoid tumor of the appendix', 'ICD-10', 'GEP', 'C7A.021', 'Malignant carcinoid tumor of the cecum', 'ICD-10', 'GEP', 'C7A.022', 'Malignant carcinoid tumor of the ascending colon', 'ICD-10', 'GEP', 'C7A.023', 'Malignant carcinoid tumor of the transverse colon', 'ICD-10', 'GEP', 'C7A.024', 'Malignant carcinoid tumor of the descending colon', 'ICD-10', 'GEP', 'C7A.025', 'Malignant carcinoid tumor of the sigmoid colon', 'ICD-10', 'GEP', 'C7A.026', 'Malignant carcinoid tumor of the rectum', 'Malignant carcinoid tumor of the large intestine, unspecified', 'ICD-10', 'GEP', 'C7A.029', 'portion', 'ICD-10', 'GEP', 'C7A.092', 'Malignant carcinoid tumor of the stomach', 'ICD-10', 'GEP', 'C7A.094', 'Malignant carcinoid tumor of the foregut, unspecified', 'ICD-10', 'GEP', 'C7A.095', 'Malignant carcinoid tumor of the mid-gut, unspecified', 'ICD-10', 'GEP', 'C7A.096', 'Malignant carcinoid tumor of the hindgut, unspecified', 'ICD-10', 'GEP', 'C25.4', 'Malignant neoplasm of endocrine pancreas', 'ICD-9', 'LUNG', '209.21', 'Malignant carcinoid tumor of the bronchus and lung', 'ICD-10', 'LUNG', 'C7A.090', 'Malignant carcinoid tumor of the bronchus and lung', 'ICD-9', 'AMBIGUOUS', '209.20', 'Malignant carcinoid tumor of unknown primary site', 'ICD-9', 'AMBIGUOUS', '209.29', 'Malignant carcinoid tumor of other sites', 'Malignant poorly differentiated neuroendocrine carcinoma, any', 'ICD-9', 'AMBIGUOUS', '209.30', 'site', 'ICD-10', 'AMBIGUOUS', 'C7A.00', 'Malignant carcinoid tumor of unspecified site', 'ICD-10', 'AMBIGUOUS', 'C7A.098', 'Malignant carcinoid tumors of other sites', 'ICD-10', 'AMBIGUOUS', 'C7A.1', 'Malignant poorly differentiated neuroendocrine tumors', 'ICD-10', 'AMBIGUOUS', 'C7A.8', 'Other malignant neuroendocrine tumors', '65']['NET-PRO Protocol v1.3', 'April 2022', 'APPENDIX B: NET Computable Phenotype - technical specification (SAS code)', 'NET-PRO Computable Phenotypes and Approaches for Recruitment', 'Overview', 'The NET-PRO recruitment approach is similar to the ADAPTABLE pragmatic clinical trial. Teams at each', 'site will contact potentially eligible patients by electronic/ground mail or will approach them in person', 'at the clinic. Understandably, each site may have a preference for a particular form of contact that will', 'optimize their enrollment.', 'In order to accommodate these varied approaches, we have developed a multi-pronged approach that', 'leverages existing data sources to identify potential enrollees. They include:', 'Phenotypes that use diagnosis codes in electronic health record (EHR) data in clinical data', 'research warehouses or most recent PCORnet Common Data Model (CDM) refresh.', \"A phenotype is provided for using these data for low-touch recruitment: 'High positive\", \"predictive value phenotype'\", 'A phenotype is provided for use when resources can confirm eligibility first, e.g. chart', 'review or in clinic recruitment: \"High sensitivity phenotype\"', 'Phenotypes that use data from institutional tumor registries', 'These data have a typical lag time of one year (depending on the institution), but an', 'excellent phenotype is provided for using this data source as part of a low-touch', 'recruitment strategy', 'This document describes the advantages and disadvantages of each data source and provides technical', 'specifications for computable phenotypes that are appropriate for different recruitment strategies. For', 'example, study sites that plan to recruit from their clinics or conduct chart reviews before recruiting may', 'find it most effective to use a highly sensitive phenotype to identify potential participants and verify', 'eligibility through chart review or in the context of a clinic visit; staff could screen out the false positives', \"that would be flagged with such a phenotype. Sites that plan to recruit by 'low-touch' via e-mail or\", 'ground mail without prior chart review to confirm eligibility, however, will need a phenotype with high', 'positive predictive value (PPV) to maximize the possibility that contacted patients actually have a', 'neuroendocrine/carcinoid tumor (NET) diagnosis. (There is generally a trade-off between PPV and', 'sensitivity; higher PPV is associated with lower sensitivity and higher sensitivity is associated with lower', 'PPV.)', 'The validity of each computable phenotype is also discussed. Where available, results from validation', 'studies performed at the University of lowa Coordinating Center (UICC) are provided. Each site is', 'encouraged to conduct its own validation studies, and the UICC can provide assistance for this based on', 'its experience.', 'It is useful to remember that prospective enrollees will confirm their eligibility by responding to', 'eligibility questions early in the enrollment process. This will serve as a final check in case the phenotype', 'mistakenly identifies someone as having a qualifying NET. The recruiting materials have been worded', 'carefully to minimize the possibility that a potential enrollee is alarmed to be contacted for a study', 'focused on NETs.', 'Following the ADAPTABLE example, the UICC will continue to develop and refine these computable', 'phenotypes to maximize their performance. This will happen through the life of the project.', 'Phenotypes that use diagnosis codes in electronic health record (EHR) data (research warehouse or', 'CDM)', '66']\n\n###\n\n", "completion": "END"}